デフォルト表紙
市場調査レポート
商品コード
1363926

頸部ジストニア治療の世界市場:2023-2030年

Global Cervical Dystonia Treatment Market 2023-2030

出版日: | 発行: Orion Market Research | ページ情報: 英文 120 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.87円
頸部ジストニア治療の世界市場:2023-2030年
出版日: 2023年09月18日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の頸部ジストニア治療市場は、予測期間中にCAGR 7.8%の大幅な成長が見込まれています。頸部ジストニアは、首の筋肉が不随意に収縮する神経疾患です。これにより、頭部が片側に傾いたり、ねじれたり、顎が上下、前方、後方に引っ張られたりします。市場成長を促進する主な要因としては、頸部ジストニアの有病率の増加が挙げられます。National Organization for Rare Disorders, Inc.(NORD)によると、米国では推定6万人が頸部ジストニアを患っています。さらに、世界中の推定有病率は10万人あたり5~30例です。このような要因により、頸部ジストニアの効果的な治療に対する需要が大幅に増加しています。ボツリヌス毒素注射/薬は、最も効果的で忍容性の高い治療法と考えられています。しかし、脳深部刺激療法(DBS)、幹細胞療法、遺伝子療法など、新しく革新的な治療法もいくつか開発されています。

セグメント別展望

ボツリヌス毒素製剤が世界の頸部ジストニア治療市場を独占する

薬物タイプの中では、ボツリヌス毒素のサブセグメントが市場で大きなシェアを占めると予想されます。ボツリヌス毒素は、その高い有効性と安全性により、頸部ジストニアの治療に使用される最も一般的な薬剤です。そのため、世界中でボツリヌス毒素製剤の継続的かつ着実な開発・承認活動が行われています。例えば、2021年に米国FDAはDaxxifyという新しいボツリヌス毒素薬を承認しました。これはより強力なボツリヌス毒素で、頸部ジストニアの治療において旧来のボツリヌス毒素薬よりも有効であることが示されています。このような承認活動により、頸部ジストニアの効果的な治療法としてボツリヌス毒素注射や薬剤の採用が増加すると思われます。

地域別展望

欧州地域が世界の頸部ジストニア市場で圧倒的なシェアを占める

すべての地域の中で、欧州地域が世界の頸部ジストニア市場でかなりのシェアを占めると予想されています。この成長は主に、同地域で頸部ジストニアの有病率が上昇していることに起因しています。Dystonia UK Organizationによると、最も一般的なジストニアは頸部ジストニアで、英国では約18,000人の成人が罹患しています。その結果、効果的な治療を提供することで地域全体の頸部ジストニアの数を減らすために、特に提携や合併などの様々な戦略的イニシアチブの採用がかなり増加しています。例えば、2023年8月、IPSENは、頸部ジストニアに苦しむ人々のアンメットニーズを明らかにするために、Dystonia Europeとのコラボレーションを発表しました。このプロジェクトには、英国、フランス、イタリアの頸部ジストニア患者15人の初診から日常生活までの体験を記録した史上初の頸部ジストニア患者体験マップの共同作成も含まれ、Orphanet Journal of Rare Diseaseに掲載されました。

目次

第1章 レポート概要

  • 業界の現状分析と成長可能性の展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • AbbVie Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Ipsen Pharma
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Merz Pharma GmbH & Co.KGaA.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Revance Therapeutics, Inc., Hint, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • USWM, LLC
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 世界の頸部ジストニア治療市場:薬剤タイプ別
    • ボツリヌス毒素
    • 抗コリン薬
    • ドパミン作動薬
    • その他
  • 世界の頸部ジストニア治療市場:用途別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他(専門ドラッグストア)
  • 世界の頸部ジストニア治療市場:エンドユーザー別
    • 病院
    • クリニック
    • その他(臨床研究機関)

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Addex Pharma SA
  • Akorn Inc
  • Almirall, S.A.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • BIOGEN INC.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • DAIICHI SANKYO Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Galderma S.A.
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Lannett Co., Inc.
  • Mylan Pharmaceutical Pvt. Ltd.
  • Novartis AG.
  • Pfizer Inc.
  • Piramal Grp.
  • SANOFI
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Ind., Ltd.
  • Teva Pharmaceutical Ind., Ltd.
  • UCB Biopharma SRL.
図表

LIST OF TABLES

  • 1. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL CERVICAL DYSTONIA BOTULINUM TOXIN TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL CERVICAL DYSTONIA ANTICHOLINERGIC AGENTS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CERVICAL DYSTONIA DOPAMINERGIC AGENTS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL OTHER TYPE OF CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CERVICAL DYSTONIA TREATMENT FOR RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CERVICAL DYSTONIA TREATMENT FOR ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CERVICAL DYSTONIA TREATMENT FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL CERVICAL DYSTONIA BOTULINUM TOXIN TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL CERVICAL DYSTONIA ANTICHOLINERGIC AGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CERVICAL DYSTONIA DOPAMINERGIC AGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL OTHER TYPE OF CERVICAL DYSTONIA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY APPLICATION, 2022 VS 2030 ($ MILLION)
  • 7. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITAL PHARMACY MARKET SHARE BY REGION, 2022 VS. 2030 (%)
  • 8. GLOBAL CERVICAL DYSTONIA TREATMENT FOR RETAIL PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CERVICAL DYSTONIA TREATMENT FOR ONLINE PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 ($ MILLION)
  • 12. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CERVICAL DYSTONIA TREATMENT FOR CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027701

Title: Global Cervical Dystonia Treatment Market Size, Share & Trends Analysis Report Market by Drug Type (Botulinum toxin, Anticholinergic agents, Dopaminergic agents, and Others), by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and by End-User (Hospitals, Clinics, and Others)Forecast Period (2023-2030).

The global cervical dystonia treatment market is anticipated to grow at a considerable CAGR of 7.8% during the forecast period. Cervical dystonia is a neurological disorder that causes the muscles in the neck to contract involuntarily. This can cause the head to lean or twist to one side, or the chin to pull up, down, forward, or backward. Primary factor propelling the market growth includes the increasing prevalence of cervical dystonia. According to the National Organization for Rare Disorders, Inc. (NORD), an estimated 60,000 people in the US are suffering with cervical dystonia. Furthermore, the estimated prevalence ranges from 5 to 30 cases per 100,000 individuals around the globe. Owing to such factors, there is significant increase in the demand for effective treatments of cervical dystonia. Botulinum toxin injections/ medications are considered the most effective and well-tolerated treatment. However, there are several developments of new and innovative treatment such as deep brain stimulation (DBS), and stem cell therapy, gene therapy, among others.

Segmental Outlook

The global cervical dystonia treatment market is segmented based on drug type, application and end-user type. Based on drug type, the market is segmented into botulinum toxin, anticholinergic agents, dopaminergic agents, and others. Based on application, the market is sub-segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Based on end-user, the market is sub-segmented into hospitals, clinics and others. Among the application, the hospital pharmacy is expected to hold a considerable share of the market, as most of the drugs prescribed for the treatment of cervical dystonia are not authorized to sale such drugs.

Botulinum Toxin Drug Type to Dominate the Global Cervical Dystonia Treatment Market

Among the drug type, the botulinum toxin sub-segment is expected to hold a prominent share of the market. It is the most common type of drug used to treat cervical dystonia owing to its high efficacy and safety. Thus, there is continuous and steady development and approval activities for botulinum toxin drugs around the globe. For instance, in 2021, the US FDA approved a new botulinum toxin medication named Daxxify. It is a more potent botulinum toxin that has been shown to be more effective than older botulinum toxin medications in treating cervical dystonia. Such approval activities will lead to an increase in the adoption of botulinum toxin injections and medications as the effective treatment of cervical dystonia.

Regional outlooks

The global cervical dystonia treatment market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, North America is expected to dominate the market, owing to the presence of well-established research institutes and hospitals for treatment of cervical dystonia.

European Region to Hold a Prominent Share of the Global Cervical Dystonia Market

Among all regions, the European region is anticipated to hold a considerable share of the global cervical dystonia market. The growth is primarily owing to the rising prevalence of cervical dystonia in the region. According to the Dystonia UK Organization, the most common dystonia is the neck dystonia, which affects around 18,000 adults in the UK. Resultantly, there is a considerable increase in the adoption of various strategic initiatives such as collaborations and mergers, among others to reduce the number of cervical dystonia across the region by providing effective treatment. For instance, in August 2023, IPSEN announced its collaboration with Dystonia Europe to help uncover the unmet needs of people living with cervical dystonia. The project included the co-creation of the first ever cervical dystonia patient experience map, published in the Orphanet Journal of Rare Disease, which charted the experiences of 15 people living with cervical dystonia in the UK, France and Italy, from initial diagnosis to living with the condition day-to-day.

Market Players Outlook

The major companies serving the global cervical dystonia treatment market include AbbVie Inc., Ipsen Pharma, Merz Pharma GmbH & Co.KGaA., Revance Therapeutics, Inc., Hint, Inc., and USWM, LLC among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in August, 2023 , the Food and Drug Administration approved Daxxify (DaxibotulinumtoxinA-lanm; Revance Therapeutics, Nashville, TN) for its first therapeutic indication for injection to treat cervical dystonia in adults.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global cervical dystonia treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Ipsen Pharma
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Merz Pharma GmbH & Co.KGaA.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Revance Therapeutics, Inc., Hint, Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. USWM, LLC
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cervical Dystonia Treatment Market by Drug Type
    • 4.1.1. Botulinum Toxin
    • 4.1.2. Anticholinergic Agents
    • 4.1.3. Dopaminergic Agents
    • 4.1.4. Others
  • 4.2. Global Cervical Dystonia Treatment Market by Application
    • 4.2.1. Hospital Pharmacy
    • 4.2.2. Retail Pharmacy
    • 4.2.3. Online Pharmacy
    • 4.2.4. Others (Specialty Drug Stores)
  • 4.3. Global Cervical Dystonia Treatment Markey by End-User
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Others (Clinical Research Organizations)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Addex Pharma SA
  • 6.2. Akorn Inc
  • 6.3. Almirall, S.A.
  • 6.4. Apotex Inc.
  • 6.5. Astellas Pharma Inc.
  • 6.6. BIOGEN INC.
  • 6.7. Boehringer Ingelheim International GmbH
  • 6.8. Bristol Myers Squibb Co.
  • 6.9. DAIICHI SANKYO Co., Ltd.
  • 6.10. Dr. Reddy's Laboratories Ltd.
  • 6.11. Eisai Co., Ltd.
  • 6.12. Galderma S.A.
  • 6.13. H. Lundbeck A/S
  • 6.14. Johnson & Johnson Services, Inc.
  • 6.15. Kyowa Kirin Co., Ltd.
  • 6.16. Lannett Co., Inc.
  • 6.17. Mylan Pharmaceutical Pvt. Ltd.
  • 6.18. Novartis AG.
  • 6.19. Pfizer Inc.
  • 6.20. Piramal Grp.
  • 6.21. SANOFI
  • 6.22. Sumitomo Pharma Co., Ltd.
  • 6.23. Sun Pharmaceutical Ind., Ltd.
  • 6.24. Teva Pharmaceutical Ind., Ltd.
  • 6.25. UCB Biopharma SRL.